A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

Recruiting now · Phase 2

Conditions studied: Metastatic Colorectal Cancer

In brief

This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.

Key facts

Study ID

NCT06493760

Run by

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

People needed

130

Starts

2024-09-03

Expected to finish

2027-06-01

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and/or females over age 18
• Histologically and/or cytologically documented metastatic colorectal cancer confirmed .
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• Expected survival >=12 weeks.
• Signed informed consent form.

You may not qualify if…

• Known uncontrolled or symptomatic central nervous system metastatic disease.
• Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria [NCI CTCAE] v.5.0).
• Inadequate organ or bone marrow function.
• Pregnant or breast-feeding woman.
• Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it is running

• Liu Tianshu — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.